What Tecnofarma does

Tecnofarma, now operating as Adium Chile, is a Chilean pharmaceutical laboratory and subsidiary of Grupo Adium, a pan-regional pharmaceutical group with over 50 years of experience in Latin America. The company commercializes a broad portfolio of proprietary and in-licensed pharmaceutical products across multiple therapeutic areas — including oncology (Decapeptyl), endocrinology/metabolism (Tirzepatide, a GIP therapy), and other specialties — to physicians and patients primarily in Chile. Its operations are supported by in-house manufacturing capabilities, R&D functions, and pharmacovigilance systems, with the broader Adium Group maintaining proprietary commercial operations in 18 Latin American countries.

The company runs an enterprise field sales go-to-market model, deploying a direct sales force to physicians and healthcare providers, and complements this with a regional distribution network through the Adium Group infrastructure. A parallel sub-brand, Vertismed, operates a specialized channel within the portfolio. Adium Chile has positioned itself as the "partner of choice" for global biotechnology and innovation companies seeking to enter or expand in Latin America, offering pan-regional capabilities in regulatory affairs, supply chain, quality assurance, compliance, and commercial support under long-term agreements.

Revenue is generated through one-time pharmaceutical product sales across licensed and proprietary therapeutics, with a publicly available PDF price list governing Chilean market pricing. The company recently rebranded from Tecnofarma to Adium Chile to align with the Grupo Adium corporate identity while preserving its therapeutic portfolio and physician/patient mission. No revenue, funding, M&A, or headcount-trend data is publicly disclosed.

Name

Tecnofarma

Legal name

Adium Chile

Website

https://tecnofarma.cl

Company type

Private

Founded year

1970

Operating status

Operating

Headcount range

251–500 employees

Short description

Tecnofarma (Adium Chile) is a Chilean pharmaceutical laboratory and subsidiary of Grupo Adium that commercializes a broad multi-therapeutic portfolio to physicians and patients in Chile and across 18 Latin American countries.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Pharmaceutical manufacturing
• Therapeutic treatments
• Pharmaceutical distribution
• Drug development
• Pharmaceutical R&D

Headquarters

HQ city

Providencia

HQ country

Argentina

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Sale of proprietary and licensed pharmaceutical products across multiple therapeutic areas to healthcare providers and patients in Latin America. The company has a consolidated portfolio developed over 50+ years, offering innovative and high-quality therapeutic solutions.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Tecnofarma (now Adium Chile) is a pharmaceutical laboratory that develops, manufactures, and distributes innovative therapeutic products across multiple therapeutic areas to physicians and patients in Chile and Latin America. The company is part of Grupo Adium, which has own operations in 18 Latin American countries and serves as a regional partner for global biotech companies seeking market entry. Its portfolio includes products such as Decapeptyl, Dicasen, and Tirzepatide, supported by in-house manufacturing, R&D, and pharmacovigilance capabilities.

Product overview

Adium Chile (formerly Tecnofarma) is a pharmaceutical laboratory operating as part of the Adium Group, a leading pharmaceutical company in Latin America with over 50 years of experience. The company offers a broad portfolio of innovative, high-quality therapeutic solutions across multiple therapeutic areas including endocrinology/metabolism (Tirzepatide), oncology (Decapeptyl), and other specialized treatments (Dicasen). The product portfolio is delivered through their own commercial operations in Chile, supported by regional manufacturing capabilities and pharmacovigilance systems. The company transitioned from Tecnofarma branding to Adium while maintaining its therapeutic area focus and patient care mission.

Differentiator

Problem solved

Functional benefit

Brands

• Vertismed: A division or sub-brand referenced at cl.vertismed.com

Products and services

• Decapeptyl Pharmaceutical product in Adium Chile's therapeutic portfolio, with a dedicated video resource available on the company's website. It is offered to physicians and patients as part of the company's broad pharmaceutical range.
• Dicasen Pharmaceutical product offered by Adium Chile, supported by online and in-person experience resources. It forms part of the company's specialized therapeutic offerings.
• Tirzepatide Pharmaceutical product focused on GIP (Glucose-dependent Insulinotropic Polypeptide) therapy, offered as part of Adium Chile's endocrinology and metabolism therapeutic portfolio.

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Global Biotech and Innovation CompaniescoreStrategic or Co-development PartnerAdium Chile serves as the 'partner of choice' for global biotech and innovative pharmaceutical companies seeking to expand into Latin America. The company has long-term agreements with recognized biotechnology and innovation companies for the promotion and distribution of their products across the region. Adium provides pan-regional capabilities including regulatory affairs, supply chain management, quality assurance, and commercial support.

Scale indicators3 records

Recent moves5 records

Expansion highlights6 records

Direct peers

• Hyperapharma (Hypera Pharma): Brazilian pharmaceutical company with broad branded and OTC portfolio and pan-LATAM reach, comparable in scale, regional footprint, and therapeutic breadth to Adium Chile.
• Biolab Farmacêutica: Brazilian pharmaceutical company focused on branded and innovative products across multiple therapeutic areas, with growing LATAM distribution — comparable as a regional branded-pharma specialist.
• Eurofarma Laboratórios: Brazilian-headquartered pharmaceutical company with extensive LATAM presence, broad innovative and generic portfolio, in-house manufacturing, and partnerships with global biotechs — closely comparable to Adium Chile's regional distribution and partnership-led model.
• Grupo EMS: One of the largest pharmaceutical companies in Brazil and Latin America, with broad therapeutic coverage, in-house manufacturing, and significant regional distribution — a direct comparator on LATAM pharma scale and portfolio breadth.
• Megalabs: Pan-LATAM pharmaceutical group operating across multiple Latin American countries with a diversified portfolio and partner-driven commercial model, structurally comparable to Grupo Adium's regional platform strategy.
• Laboratorios Roemmers: Argentine-headquartered pharmaceutical group with strong presence across LATAM, broad therapeutic portfolio, and in-house manufacturing — directly comparable as a Southern Cone pharma operator with regional ambitions.
• Genomma Lab Internacional: Mexican-based pharmaceutical company with strong LATAM distribution across multiple therapeutic areas, employing a partner and licensing-driven model similar to Adium Chile's biotech in-licensing approach.
• Aché Laboratórios Farmacêuticos: Major Brazilian pharmaceutical manufacturer with broad prescription and OTC portfolio, in-house manufacturing, and partnerships with global innovators — a comparable LATAM pharma operator with similar distribution and partnership dynamics.

Broad incumbents

• Bayer (Pharmaceutical Division): Global pharmaceutical incumbent with established LATAM operations and broad therapeutic portfolio including cardiometabolic products; serves as a benchmark incumbent competitor rather than a niche-focused LATAM player.
• Sanofi (LATAM operations): Global pharmaceutical company with significant LATAM commercial infrastructure and a broad portfolio spanning oncology, cardiology, endocrinology, and rare diseases — overlaps with Adium Chile's therapeutic mix and regional reach.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/adiumchile
• LinkedInlinkedin.com/company/tecnofarma-chile
• Instagraminstagram.com/adiumchile

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tecnofarma